Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study Evaluating INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

NCT05879822 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT05879822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05879822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study Evaluating INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 30, 2023
Completion date
September 30, 2026
Enrollment
73 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor